tbuckley/cabot-search huggingface dataset:
SP0096 Advances in the management of osteoporosis
Authors: C. Roux
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> The number of fractures related to osteoporosis is expected to increase in the next few decades, because of the increasing number of frail elderly patients at high risk of falls and fractures. Guidelines are available worldwide for the screening of patients at high risk of fracture, and for appropriate treatment including non pharmacological treatments for falls prevention: A number of questions will be discussed during the session. Why should we treat? Because the burden of osteoporosis is related to fractures, and their consequences on morbidity, and even on mortality for the more severe ones. When should we treat? There is an immediate increase of sustaining a new fracture in the 2–3 years following a first one; this represents a unique window of opportunity for treatment. How should we treat? Treatments are effective in prevention of fracture, and re fracture, providing that we use the more effective treatment, with the appropriate sequences. How long should we treat? The treat to target strategy must be used in patients having a low bone mineral density, and obtaining a T score above – 2 is a reachable target. A current challenge is the patients' view on side effects of the treatments; although they are very rare, their perception is very high. A number of qualitative studies sought to assess patients' fears and beliefs and provide wordings to clarify the fracture risk concept. The prevention of fragility fractures is now within our reach. <h3>Disclosure of Interest</h3> None declared
Applications for Epi- vs. Trans-illumination and spectral unmixing for non-invasive fluorescence imaging of molecular targets in small laboratory animals
Authors: Ning Zhang, Heng Xu, Min Chen, Muhammad Ahsan, Kshitij Modi, Steven Smith, Peter Lassota
Journal: Cancer Research (2007)

LB-85  Non-invasive fluorescence imaging of small laboratory animals may provide a valuable addition to luciferase-based bioluminescence imaging and may add important information about molecular status of the disease including early detection of the response to treatment. However, comparing to bioluminescence, fluorescence imaging still faces multiple challenges. High background and less than favorable balance between the throughput and the quantitativeness of images are among the most important ones. Here we present results of non-invasive fluorescence imaging of various probes in athymic nude, and in SCID/beige mice with the new IVIS Spectrum system. This system combines the high throughput of the bioluminescence with all the features needed for fluorescence imaging. Subcutaneously implanted Quantum Dots 800 (QD800) were easily detectable using epi-illumination, while the same number of QD 800 implanted intramuscularly could be detected only with trans-illumination. This indicates that both epi- and trans-illumination features are useful, depending on the location of the fluorescent probe. Background animal fluorescence subtraction in the trans-illumination mode increased the signal to background ratio by more that an order of magnitude. Imaging of the SK-OV-3 tumors simultaneously labeled with VivoFluor 680 and VivoFluor 750 HER2/neu probes showed that a careful selection of the narrow band excitation (10 available) and emission (18 available) filters can result in complete separation of the signals. We will present and discuss two strategies for selecting the optimal sets of filters based on “best excitation” and “best emission” approaches, including corrections for in vitro to in vivo transition. For cases when substantial separation of the signals from two fluorescent probes is impossible to accomplish by selection of emission and excitation filters, we developed a spectral unmixing approach, which allows us to separate the signals based on the registered real spectral properties of the probes. We will show spectral unmixing results for the VivoFluor 680 and VivoFluor 750.  Key Words: IVIS-Spectrum, fluorescence imaging, Unmixing, VivoFluor
The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers
Authors: Giovanni Germano, Nabil Amirouchene-Angelozzi, Giuseppe Rospo, Alberto Bardelli
Journal: Cancer Discovery (2018)

The mismatch repair (MMR) system which detects and corrects base mismatches and insertions and deletions that occur during DNA synthesis is deregulated in approximately 20% of human cancers. MMR-deficient tumors have peculiar properties, including early-onset metastatic potential but generally favorable prognosis, and remarkable response to immune therapy. The functional basis of these atypical clinical features has recently started to be elucidated. Here, we discuss how the biological and clinical features of MMR-deficient tumors might be traced back to their ability to continuously produce new somatic mutations, leading to increased levels of neoantigens, which in turn stimulate immune surveillance. SIGNIFICANCE: Tumors carrying defects in DNA MMR accumulate high levels of mutations, a feature linked to rapid tumor progression and acquisition of drug resistance but also favorable prognosis and response to immune-checkpoint blockade. We discuss how the genomic landscape of MMR-deficient tumors affects their biological and clinical behaviors.
Dupilumab Treatment for Generalized Prurigo Nodularis
Authors: Kristen M. Beck, Eric J. Yang, Sahil Sekhon, Tina Bhutani, Wilson Liao
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Regionalization of Complex Cancer Surgery
Authors: Nabil Wasif, David A. Etzioni
Journal: JAMA Network Open (2018)

Benjamin J. Resio, MD; Alexander S. Chiu, MD; Jessica R. Hoag, PhD; Lawrence B. Brown, MHS; Marney White, PhD, MS; Audry Omar, MA; Andres Monsalve, MD; Andrew P. Dhanasopon, MD; Justin D. Blasberg, MD; Daniel J. Boffa, MD
MicroRNA-mediated loss of PDEF protein expression results in progression to more invasive breast cancer
Authors: Victoria Findlay, David Turner, Omar Moussa, Dennis Watson
Journal: Cancer Research (2008)

1569   The purpose of this study is to elucidate possible mechanism(s) of PDEF protein loss during breast cancer progression. Cancer death is due in large part to metastases. One of the more interesting challenges is to understand the cellular changes that occur during progression towards more invasive cancer. PDEF is an Ets transcription factor with expression restricted to tissues with high epithelial content, including breast, prostate and colon. At the mRNA level PDEF overexpression has been proposed as a diagnostic marker of invasive cancer. However, PDEF protein is often reduced in invasive tissue and lost in invasive cancer cells. Indeed, re-expression of PDEF protein in invasive cells lines inhibits cell growth, migration and invasion. To date, the processes involved in the loss of PDEF protein during cancer progression have not been elucidated. The emerging field of microRNAs (miRNAs) has led to the functional discovery of their role in many types of cancer. However, the identification and validation of specific targets has been limited. miRNAs function post-transcriptionally by promoting either mRNA degradation or inhibiting mRNA translation. To explore the potential role for miRNAs in the post-transcriptional regulation of PDEF, a bioinformatics approach identified multiple miRNA recognition sequences within the 3’ untranslated region (UTR) of PDEF. Two miRNAs, miRNA 204 (miR204) and 510 (miR510) were found to be elevated in breast cancer cell lines having high RNA and low PDEF protein levels. Two cell lines were selected as models to test the functional role of these miRNAs in regulation of PDEF protein expression: CAMA-1 (high mRNA, low protein) and MCF7 (high mRNA, high protein). Inhibition of miR204 or miR510 by antisense oligoribonucleotides in CAMA-1 results in an increase in PDEF protein levels without significant affects on PDEF mRNA. Reciprocal overexpression of either miR204 or miR510 in MCF7 cells results in a loss of PDEF protein, without significantly affecting the levels of PDEF mRNA. The functional consequences of miRNA-mediated loss of PDEF include an altered cellular morphology, increased cellular migration and invasion and a more transformed phenotype. Furthermore, we demonstrate that these cellular changes occur through the altered regulation of known PDEF transcriptional targets. In addition, we show for the first time that expression of miR-204 and miR-510 are elevated in human breast tumor samples compared to matched non-tumor samples. Collectively, this study provides for the first time a mechanism for the loss of PDEF protein expression and a unique oncogenic role for these miRNAs during metastatic breast cancer progression.
Abstract 20772: In a Multi-Center Trial Less Invasive Ventricular Enhancement (LIVE TM) Technique With the Revivant TM System (Bioventrix) Significantly Improves LV Function in HFrEF Patients. A 12 Months-CMR-Follow-Up Study
Authors: Lukas Stoiber, Tomas Lapinskas, Seyedeh Mahsa Zamani, Christoph Klein, Christoph Schmitz, David Schickling, Lon S Annest, Burkert Pieske, Sebastian Kelle
Journal: Circulation (2017)

Introduction: Ischemic cardiomyopathy (ICM) is the most common type of heart failure with reduced ejection fraction (HFrEF). Surgical ventricular reconstruction (SVR) by open-chest-surgery is an op...
Оцінка ефективності гепатопротектора Гепа Веда у хворих із патологією печінки
Authors: Yu.M. Stepanov, N.D. Chukhriienko, А.V. Salenko, Yu.S. Breslavets, M.L. Pleschenko, Zh.V. Stepanova
Journal: GASTROENTEROLOGY (2020)

У статті наведені результати ефективності монотерапії гепатопротектором Гепа Веда у хворих із патологією печінки. Встановлено вірогідне зниження рівня амінотрансфераз у хворих на неалкогольний стеатогепатит та тенденцію до зниження у хворих на хронічний гепатит, асоційований із вірусом С, що засвідчує ефективність даного гепатопротектора.
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro
Authors: R. Salpini, M. Surdo, M.F. Cortese, G.A. Palumbo, L. Carioti, G. Cappiello, A. Spanò, P. Trimoulet, H. Fleury, J. Vecchiet, C. Pasquazzi, C. Mirabelli, R. Scutari, A. Sacco, M. Alkhatib, G. Missale, S. Francioso, L. Sarmati, M. Andreoni, M. Angelico, F. Ceccherini-Silberstein, M. Levrero, C.F. Perno, L. Belloni, V. Svicher
Journal: Clinical Microbiology and Infection (2018)
Clinical-Pathological Features of Non-Transfusion Dependent Thalassemia in Adults — a Single Center Study in Hong Kong
Authors: Ka Lok Luke Chan, Vivien W M Mak, Kate F S Leung, Joyce H Y Kwong, Nelson C N Chan, Kelvin C K Cheng, Natalie P H Chan, Daniel H F Fong, Stephen C C Choy, Carmen K M Ng, Johnny K F Ma, Michael L G Wong, Margaret Ng, Harold K K Lee
Journal: Blood (2018)
Abstract 15520: High Intensity Exercise Training Improves Ventricular-Arterial Coupling
Authors: Michinari Hieda, Satyam Sarma, Erin Howden, Takashi Tarumi, Qi Fu, Rong Zhang, Benjamin D. Levine
Journal: Circulation (2017)

Introduction: The “dynamic” Starling mechanism, reflecting time-varying ventricular-arterial coupling, is impaired with sedentary aging. The impaired ventricular-arterial coupling may impact cardia...
Abstract 15321: Impact of Exercise Right Ventricular Performance on Functional Capacity in Patients Undergoing Mitral Valve Surgery for Chronic Ischemic Mitral Regurgitation: A Longitudinal Study
Authors: Carlo Fino, Attilio Iacovoni, Philippe Pibarot, Julien Magne, Massimo Caputo, Maurizio Merlo, Lorenzo Galletti, Michele Senni, Paolo Ferrero, Diego Cugola, Caterina Simon, Diego Bellavia
Journal: Circulation (2017)

Introduction: Data on the exercise hemodynamic performance of the right ventricle (RV) in patients undergoing mitral valve surgery (MVS) for chronic ischemic mitral regurgitation (CIMR) are sparse....
The stability and variations in the reporting of the CAGE-AID screening questionnaire in cancer patients.
Authors: Tonya Edwards, Joseph Anthony Arthur, Neeraj Joshi, Leela Kuriakose, Manju P Joy, Seyedeh Dibaj, Donna S. Zhukovsky
Journal: Journal of Clinical Oncology (2018)

224 Background: The CAGE-AID questionnaire (CA) is a 4-item patient reported validated screening tool has been used to assess risk of aberrant drug related behaviors in cancer patients receiving opioids. Consistency of responses to the CA between settings is lacking. We evaluated the frequency of CA positivity in each setting and change in score (+ or -) between the first inpatient supportive care consultation and the first outpatient follow up visit within 3 months. Methods: A retrospective chart review was conducted to ascertain CA scores and clinical and demographic characteristics of consecutive adult patients who were initially seen during inpatient consultation (T1) and had an outpatient follow up within 3 months (T2). CA positivity was defined as a score of ≥2 in males or ≥1 in females, with score at T2 considered the gold standard. Results: ±SD) was 122 mg (150) at T2. CA was completed for 87% of T1 patients and 94% at T2. Scores are noted below. Hispanics (23%) were more likely to be CA positive as compared with Caucasians (15%) and African Americans (11%), p= 0.02. Between T1 and T2, CA score changed from negative to positive in 4% and positive to negative in 1% of patients. The Kappa coefficient for agreement of CA between T1 and T2 was 0.74 (0.62, 0.86), p= 0.02. Conclusions: The rate of completion and consistency of patient responses to the CA was high irrespective of clinical setting. Between 10-13% of patients with advanced cancer are at increased risk for aberrant opioid use. Further studies are needed to evaluate the reasons for a change in CA scores between T1 to T2 in some patients so as not to miss those at higher risk for aberrant behaviors in need of additional monitoring and support. [Table: see text]
Unusual Focal Muscle FDG Activity Related to Altered Biomechanics
Authors: Eleanor Gillis, Zhe Wen, Hongming Zhuang
Journal: Clinical Nuclear Medicine (2018)

Abstract A 20 year old man suffered severe right knee pain, especially when his right foot touched ground. The MRI findings suggested periosteal osteosarcoma, which led to a staging FDG PET/CT. The images showed not only a hypermetabolic right knee lesion but also focally elevated activity in select muscles, which was attributed to altered biomechanics. The resected lesion was pathologically proven as periosteal chondrosarcoma instead of periosteal osteosarcoma. In a follow-up period of 4 years after the surgery, there was no recurrent disease, nor any abnormality in the muscles which showed focal FDG activity on the initial FDG PET/CT.
Abstract 19783: Interaction of a Genetic Risk Score With BMI, Physical Activity, and Physical Inactivity in Relation to Venous Thromboembolism Risk
Authors: Jihye Kim, Peter Kraft, Kaitlin A Hagan, Laura B Harrington, Sara Lindstrom, Christopher Kabrhel
Journal: Circulation (2017)

Introduction: Venous thromboembolism (VTE) is a highly heritable disease (~50%). However, evidence regarding interaction of genetic predisposition to VTE with body mass index (BMI), physical activi...
Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years
Authors: Andres JM Ferreri, Marianna Sassone, Francesco Zaja, Alessandro Re, Michele Spina, Alice Di Rocco, Alberto Fabbri, Piera Angelillo, Caterina Stelitano, Maurizio Frezzato, Chiara Rusconi, Renato Zambello, Annalisa Arcari, Giovanni Bertoldero, Daniela De Lorenzo, Eloise Scarano, Stefano Volpetti, Salvatore Perrone, Teresa Calimeri, Caterina Cecchetti, Fabio Ciceri, Maurilio Ponzoni
Journal: Blood (2018)
Abstract 17661: Optical Coherence Tomography Identifies Artifactual Thin-cap Fibroatheromas: A Histologic Study
Authors: Jennifer E Phipps, Deborah Vela, Taylor Hoyt, L. Maximilian Buja, Thomas E Milner, Marc D Feldman
Journal: Circulation (2014)

Introduction: Current methods to identify thin-cap fibroatheroma (TCFA) with optical coherence tomography (OCT) are qualitative. While two mechanisms for the appearance of false TCFA have been identified and include macrophages that cause superficial shadowing and tangential light dropout, we report three new mechanisms for the appearance of false TCFAs in OCT images. Methods: 13 coronary arteries from 8 human cadaver hearts (6 male, 2 female, aged 63 ± 12 years) were imaged with OCT. OCT TCFAs were identified independently by three expert OCT readers and defined by a bright homogenous fibrous cap overlying a diffusely shadowed signal-poor region. Analysis was performed to confirm the identification of TCFA or to identify the histologic origin of the OCT TCFA appearance. Arc length of the signal-poor region of each OCT TCFA was also measured. Results: 38 OCT TCFA were identified, of which only 5 were verified with histology. Measurements of arc length and thickness of the cap are summarized in the table. Of the 33 false TCFA, three morphologic plaque types were identified: thick-cap fibroatheroma (TkFA; N=18), pathologic intimal thickening (PIT; N=10), and fibrocalcific (FC; N=5). New mechanisms for the signal-poor regions that appeared as lipid cores included loose connective tissue (N=7), neovasculature (N=3), and proteoglycans (N=4). Superficial shadowing of macrophages caused the appearance of TCFA in 5 cases. In the 18 TkFA cases, OCT underestimated the thickness of the fibrous cap (45.2 ± 4.0 μm by OCT compared to 197.5 ± 18.8 μm by histology). Conclusion: Using an arc length of greater than 90 degrees will aid in differentiating true from false TCFA. Additionally, due to incomplete light penetration, TkFA can be mistaken for TCFA. These results demonstrate that caution should be used when diagnosing vulnerable plaque with OCT.
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Authors: Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, Dafna D. Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M. Elaine Husni, Sarah Kenny, Jennifer Kwan‐Morley, Janice Lin, Paula Marchetta, Philip J. Mease, Joseph F. Merola, Julie Miner, Christopher T. Ritchlin, Bernadette Siaton, Benjamin J. Smith, Abby S. Van Voorhees, Anna Helena Jonsson, Amit Aakash Shah, Nancy Sullivan, Marat Turgunbaev, Laura C. Coates, Alice Gottlieb, Marina Magrey, W. Benjamin Nowell, Ana‐Maria Orbai, Soumya M. Reddy, Jose U. Scher, Evan Siegel, Michael Siegel, Jessica A. Walsh, Amy S. Turner, James Reston
Journal: Arthritis & Rheumatology (2018)

Objective To develop an evidence‐based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology ( ACR ) and the National Psoriasis Foundation ( NPF ). Methods We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of the evidence. A voting panel, including rheumatologists, dermatologists, other health professionals, and patients, achieved consensus on the direction and the strength of the recommendations. Results The guideline covers the management of active PsA in patients who are treatment‐naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin‐12/23 inhibitors ( IL ‐12/23i), IL ‐17 inhibitors, CTLA 4‐Ig (abatacept), and a JAK inhibitor (tofacitinib). We also developed recommendations for psoriatic spondylitis, predominant enthesitis, and treatment in the presence of concomitant inflammatory bowel disease, diabetes, or serious infections. We formulated recommendations for a treat‐to‐target strategy, vaccinations, and nonpharmacologic therapies. Six percent of the recommendations were strong and 94% conditional, indicating the importance of active discussion between the health care provider and the patient to choose the optimal treatment. Conclusion The 2018 ACR / NPF PsA guideline serves as a tool for health care providers and patients in the selection of appropriate therapy in common clinical scenarios. Best treatment decisions consider each individual patient situation. The guideline is not meant to be proscriptive and should not be used to limit treatment options for patients with PsA.
Curbing Surprise Medical Bills Can Be a Window Into Cost Control
Authors: Andrew Bindman
Journal: JAMA (2018)

positives, etc.I can tell you we have had several positives.We haven't done any kind of formal analysis yet, but we've been really pleased in terms of the demographics.A good percentage of the people that we screen have never been screened before.Also, a large percentage had at least one major risk factor for HIV.JAMA: Do you want to expand beyond DC? COPLEY: We want to be in about 6 cities in the next 3 years.But shorter-term, PG County's health department reached out to us.That's Prince George's County, where risk is really high, prevalence is really high.It's a great spot for us to be.University of Maryland is right there.They have about 40 500 students.Prince George's Community College has 44 000 students-a ton of potential volunteers there.Because PG County's in Maryland, all [our] licenses will apply in Baltimore as well.We're thinking about being in Baltimore at the beginning of next academic year.
Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma
Authors: Lucas D. Trucco, Piyushkumar A. Mundra, Kate Hogan, Pablo Garcia-Martinez, Amaya Viros, Amit K. Mandal, Nicolas Macagno, Caroline Gaudy-Marqueste, Donald Allan, Franziska Baenke, Martin Cook, Clare McManus, Berta Sanchez-Laorden, Nathalie Dhomen, Richard Marais
Journal: Nature Medicine (2018)